In the past month pharmaceutical companies have spent almost $100bn acquiring biotech companies. The FT's Sarah Neville explains why big pharma is raising its bet on the drug pipelines owned by biotechs, and why analysts expect more consolidation in 2019.&nbsp; Read more from Sarah at <a href="https://www.ft.com/content/80a21ca2-136b-11e9-a581-4ff78404524e" target="_blank">FT.com</a>. <hr> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.

What next for Detroit's carmakers

From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the business and financial stories of the moment with reporting from Financial Times journalists around the world.  Hosted on Acast. See acast.com/privacy for more information.